Clinical Trial: Electronic Eye Implant Restores Vision in 84% of Patients
The Facts
- A clinical trial involving 38 participants across 17 sites in five countries has shown that the Prima electronic eye implant can help restore vision for patients with geographic atrophy — an advanced form of dry age-related macular degeneration that affects around five million people worldwide.
- The Prima device measures 2mm by 2mm (.08 x .08 inches) with half the thickness of a human hair and is surgically placed under the retina through a procedure lasting under two hours at locations including Moorfields Eye Hospital in London.
- Patients wear augmented-reality glasses containing a video camera connected to a waistband computer that processes images using artificial intelligence and converts them into electrical signals sent to the brain via the optic nerve.
Sources Split
LEFT
CENTER
RIGHT
+2
+1
+2
+4
ESTAB
CRIT
CENTER
PRO
ESTAB
The Spin
Techno-optimist narrative
Electronic eye implants signify a revolutionary breakthrough that's transforming lives for the blind. The Prima device has achieved remarkable success, with 84% of patients regaining the ability to read letters and words after losing their sight to macular degeneration. This groundbreaking technology offers hope where none existed before — restoring independence and confidence to those facing incurable blindness.
Techno-skeptic narrative
AI-powered medical devices in ophthalmology face serious risks from biased algorithms and flawed datasets that compromise patient safety. These systems often fail to work accurately across diverse populations due to source and context bias, leading to misdiagnoses and inappropriate treatment decisions. The black-box problem and cybersecurity vulnerabilities make these technologies potentially dangerous without proper oversight.
Metaculus Prediction
The Controversies
Go Deeper
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.18.3